Lenvatinib and sorafenib for treating differentiated thyroid cancer

Published on 04 Jan 2022
Last Updated on 04 Jan 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Sorafenib 200 mg tablet; and

• Lenvatinib 4 mg and 10 mg capsules

for treating locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

Subsidy status

Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.

Lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Lenvatinib and sorafenib for treating differentiated thyroid cancer (4 Jan 2022) [PDF, 120 KB]

PES Lenvatinib and sorafenib for treating differentiated thyroid cancer (Published 4 Jan 2022) [PDF, 86 KB]